Teplizumab Could Delay Diagnosis of Type 1 Diabetes
FRIDAY, March 12, 2021 -- A single course of teplizumab treatment delays progression to type 1 diabetes (T1D) and improves beta cell function in high-risk individuals, according to a study published in the March 3 issue of Science Translational Medicine.
Emily K. Sims, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues examined the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a randomized controlled trial of individuals without diabetes at high risk for T1D who have relatives with T1D. An extended follow-up (median, 923 days) of a previous report of teplizumab treatment was conducted.
The researchers found that the median times to diagnosis were 59.6 and 27.1 months for teplizumab- and placebo-treated participants, respectively (hazard ratio, 0.457). Overall, 50 and 22 percent of teplizumab- and placebo-treated participants, respectively, remained diabetes-free. Beta-cell function was improved with teplizumab treatment, with an average on-study C-peptide area under the curve (AUC) of 1.94 versus 1.72 pmol/mL. A decline in insulin secretion before enrollment was reversed with drug treatment, followed by stabilization of the declining C-peptide AUC observed with placebo treatment. After drug treatment, proinsulin:C-peptide ratios were similar between the treatment groups.
"Any time without diabetes is important, but particularly so for those children who might have a chance to grow up without it," a coauthor said in a statement.
One author disclosed financial ties to Provention Bio, which developed the study drug.
© 2021 HealthDay. All rights reserved.
Posted: March 2021
Read this next
THURSDAY, April 8, 2021 -- For patients with chronic coronary syndrome, the prevalence of diabetes varies but is associated with increased mortality and cardiovascular events,...
FRIDAY, April 2, 2021 -- Diabetes mortality rates are higher in Blacks than Whites, with a mortality rate 2.21 times higher among Blacks than among Whites during 2013 to 2017,...
The annual meeting of the Endocrine Society was held virtually this year from March 20 to 23 and attracted participants from around the world, including clinicians, academicians,...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.